Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago.
Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG; OTCQX:RHHBY) showed that the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK led to one complete response (CR), three partial responses (PRs) and one unconfirmed PR among five evaluable pediatric patients with primary CNS tumors. STARTRK-NG enrolled pediatric patients with recurrent or refractory solid or primary CNS tumors with ROS1, NTRK or ALK1 fusions. One patient with a PR and the patient with the unconfirmed PR harbored ROS1 fusions, while the other three had NTRK fusions...